Hi Beaza79,
I agree with Edski1. In my opinion too much short term information can lead to a "Forest for the Trees" effect. I think you start reacting to short term information that may or may not have a bearing on the end game. The marjority of information discussed by the Director is in relation to general Cancer research relating to the fields they are playing in. If something was going to move the shareprice then it would need to be disclosed to the market. Directors have a vested interest in the stock they represent, they are not impartial and have a skewed perspective on their stock (from memory I think he said he was 90% invested). I have read the comments of the director and find them informative and in the extremly complex world of Cancer are benificial to stearing the followers in the right direction. However...
In todays world of corporate governance and litigation, as a chairperson of a publicly listed company (or even shareholder) would I want one of my Directors answering questions / queries on a social media platform? One slip up and a class action may not be too far away which potentially puts all shareholders money at risk. I wonder if they have checked the Directors Liability Insurance to see if posting on social media is covered should he slip up? One glass of red too many and whoops cant take it back.
I much prefer the recent PAR Development day that gave us everyone a very clear roadmap ahead and now we leave them to get on with what we pay them to do, implement the strategy and .... show me the money....
Poolboy
- Forums
- ASX - By Stock
- PAR
- Would a PAR representative on social media help??
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.20%
!
46.5¢

Would a PAR representative on social media help??, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
46.5¢ |
Change
0.010(2.20%) |
Mkt cap ! $184.8M |
Open | High | Low | Value | Volume |
45.5¢ | 48.0¢ | 44.0¢ | $534.2K | 1.168M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5245 | 45.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5245 | 0.455 |
1 | 23000 | 0.450 |
1 | 15000 | 0.445 |
1 | 10000 | 0.440 |
1 | 17857 | 0.435 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 10000 | 1 |
0.475 | 13560 | 2 |
0.480 | 110598 | 4 |
0.485 | 10000 | 1 |
0.490 | 18000 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online